Dr. Eli Muchtar, MD
Claim this profileMayo Clinic in Rochester
Studies Amyloidosis
Studies AL Amyloidosis
2 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Eli Muchtar, MD is currently running
CFT7455
for Lymphoma
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Recruiting1 award Phase 1 & 210 criteria
Daratumumab Maintenance Therapy
for Amyloidosis
This phase II trial compares shorter-duration versus longer-duration maintenance therapy with daratumumab for improving survival in patients who have received initial treatment with daratumumab for light chain (AL) amyloidosis. Maintenance therapy is treatment that is given to help keep cancer from coming back after it has disappeared following initial therapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Daratumumab is commonly prescribed as initial treatment for patients with AL amyloidosis. However, it is not known what role daratumumab may play in the maintenance therapy period of patients with AL amyloidosis. This phase II trial compares shorter duration maintenance to longer duration maintenance for improving survival in patients with AL amyloidosis.
Recruiting1 award Phase 215 criteria
More about Eli Muchtar, MD
Clinical Trial Related3 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Eli Muchtar, MD has experience with
- Daratumumab
- CFT7455
- Dexamethasone Oral
Breakdown of trials Eli Muchtar, MD has run
AL Amyloidosis
Multiple Myeloma
Non-Hodgkin's Lymphoma
Plasma Cell Neoplasm
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Eli Muchtar, MD specialize in?
Eli Muchtar, MD focuses on Amyloidosis and AL Amyloidosis. In particular, much of their work with Amyloidosis has involved treating patients, or patients who are undergoing treatment.
Is Eli Muchtar, MD currently recruiting for clinical trials?
Yes, Eli Muchtar, MD is currently recruiting for 2 clinical trials in Rochester Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Eli Muchtar, MD has studied deeply?
Yes, Eli Muchtar, MD has studied treatments such as Daratumumab, CFT7455, Dexamethasone Oral.
What is the best way to schedule an appointment with Eli Muchtar, MD?
Apply for one of the trials that Eli Muchtar, MD is conducting.
What is the office address of Eli Muchtar, MD?
The office of Eli Muchtar, MD is located at: Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States. This is the address for their practice at the Mayo Clinic in Rochester.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.